10.01.15
Chiltern is expanding its clinical development services in endocrinology and metabolism with the appointment of Randy L. Anderson, Ph.D., as senior vice president of scientific affairs.
Dr. Anderson has 30 years of industry experience with expertise in diabetes and other endocrine/metabolism disorders. He joins the company after 18 years with another major CRO, where he provided scientific leadership for the endocrinology and metabolism therapeutic area. Dr. Anderson will also serve as Chiltern’s administrative leader for its other scientific affairs experts across all therapeutic areas.
The endocrinology and metabolism area at Chiltern includes diseases of the endocrine organs and related complications: type 1 diabetes, type 2 diabetes, diabetes complications, obesity, dyslipidaemias, adrenal disorders, thyroid disorders, pituitary disorders, calcium homeostasis disorders, cardiovascular disease prevention, growth disorders, sex androgen dysfunction and other rare metabolic disease indications such as lysosomal storage disorders, Prader-Willi Syndrome and Fabry disease.
“Expanding our clinical development services for endocrinology and metabolism diseases is a direct response to client desire for collaborative partnerships in development planning, design and execution of clinical trials in this complex therapeutic area,” said Dr. Jim Esinhart, Chiltern chief executive officer. We are excited to add Dr. Anderson’s energy and leadership to our offerings in the endocrinology and metabolism therapeutic area.”
Dr. Anderson has 30 years of industry experience with expertise in diabetes and other endocrine/metabolism disorders. He joins the company after 18 years with another major CRO, where he provided scientific leadership for the endocrinology and metabolism therapeutic area. Dr. Anderson will also serve as Chiltern’s administrative leader for its other scientific affairs experts across all therapeutic areas.
The endocrinology and metabolism area at Chiltern includes diseases of the endocrine organs and related complications: type 1 diabetes, type 2 diabetes, diabetes complications, obesity, dyslipidaemias, adrenal disorders, thyroid disorders, pituitary disorders, calcium homeostasis disorders, cardiovascular disease prevention, growth disorders, sex androgen dysfunction and other rare metabolic disease indications such as lysosomal storage disorders, Prader-Willi Syndrome and Fabry disease.
“Expanding our clinical development services for endocrinology and metabolism diseases is a direct response to client desire for collaborative partnerships in development planning, design and execution of clinical trials in this complex therapeutic area,” said Dr. Jim Esinhart, Chiltern chief executive officer. We are excited to add Dr. Anderson’s energy and leadership to our offerings in the endocrinology and metabolism therapeutic area.”